CBUS Stock Summary and Trading Ideas (Cibus - Class A | NASDAQ:CBUS)

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Cibus - Class A trades on the NASDAQ stock market under the symbol CBUS.

As of December 31, 2025, CBUS stock price climbed to $1.74 with 276,480 million shares trading.

CBUS has a beta of 2.53, meaning it tends to be more sensitive to market movements. CBUS has a correlation of 0.17 to the broad based SPY ETF.

CBUS has a market cap of $91.71 million. This is considered a Micro Cap stock.

Last quarter Cibus - Class A reported $615,000 in Revenue and -$.44 earnings per share. This fell short of revenue expectation by $-655,600 and missed earnings estimates by -$.17.

The top ETF exchange traded funds that CBUS belongs to (by Net Assets): VTI, VXF, IWC, KROP, MSSM.

CBUS has underperformed the market in the last year with a return of -32.6%, while SPY returned +17.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CBUS shares. However, CBUS has outperformed the market in the last 3 month and 2 week periods, returning +34.9% and +11.5%, while SPY returned +2.7% and +0.7%, respectively. This indicates CBUS has been having a stronger performance recently.

CBUS support price is $1.59 and resistance is $1.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CBUS shares will trade within this expected range on the day.